An Evaluation of MSDC-0160, A Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer’s Disease

Alzheimer’s disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose metaboli...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Raj C, Matthews, Dawn C, Andrews, Randolph D, Capuano, Ana W, Fleischman, Debra A, VanderLugt, James T, Colca, Jerry R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153084/
https://www.ncbi.nlm.nih.gov/pubmed/24931567
http://dx.doi.org/10.2174/1567205011666140616113406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153084/
https://www.ncbi.nlm.nih.gov/pubmed/24931567
http://dx.doi.org/10.2174/1567205011666140616113406

Ejemplares similares